Brief: Oxigene announces interim phase 2 data for lead clinical candidate CA4P in neuroendocrine tumors
19/10/2015 13:00
Oct 19 (Reuters) - OXiGENE Inc OXGN.O : * Press release - Oxigene announces interim phase 2 data for lead clinical candidate ca4p (fosbretabulin) in neuroendocrine tumors * Says biomarker results in first nine subjects add to ca4p evidence of activity * Says full results are expected in the second half of 2016 * Source text for Eikon ID:nGNXVEPVVa * Further company coverage OXGN.O ((Bengaluru Newsroom; +1 646 223 8780))
Recent news on Oncotelic Therapeutics
See all newsBrief: Oncotelic Therapeutics Emerging As Leader With New Independent JV Valuation
Brief: Oncotelic Therapeutics - JV Is Preparing For A Potential Initial Public Offering On The Hong Kong Stock Exchange In Late 2026
Brief: Oncotelic Therapeutics To Sell Its Necroptosis Cancer Therapy Assets To Mosaic Immunoengineering
Brief: Oncotelic Announces Initiation Of Clinical Study In Non-Small Lung Cell Cancer
Brief: Oncotelic Initiates Clinical Trials Evaluating Ot-101 Against Pediatric Gliomas